Manufacturing industries Books
Bloomsbury Publishing PLC Why Food Matters
Book SynopsisWhat is food and why does it matter? Bringing together the most innovative, cutting-edge scholarship and debates, this reader provides an excellent introduction to the rapidly growing discipline of food studies. Covering a wide range of theoretical perspectives and disciplinary approaches, it challenges common ideas about food and identifies emerging trends which will define the field for years to come.A fantastic resource for both teaching and learning, the book features:- a comprehensive introduction to the text and to each of the four parts, providing a clear, accessible overview and ensuring a coherent thematic focus throughout- 20 articles on topics that are guaranteed to engage student interest, including molecular gastronomy, lab-grown meat and other futurist foods, microbiopolitics, healthism and nutritionism, food safety, ethics, animal welfare, fair trade, and much more- discussion questions and suggestions for further reading which help readers to think further about the iTrade ReviewA dynamite collection that brings together cutting-edge scholarship from leading figures working in food studies and anthropology. * DAVID SUTTON, PROFESSOR OF ANTHROPOLOGY, SOUTHERN ILLINOIS UNIVERSITY, USA *With an introduction that synthesizes compelling themes connecting anthropology to political economy, science and technology studies, and ontological concerns, this book speaks to a range of scholars in many fields. * BRAD WEISS, PROFESSOR OF ANTHROPOLOGY, COLLEGE OF WILLIAM & MARY, USA *This collection of case studies from across the world offers a provocative unsettling of what we think food is. Why Food Matters takes food studies exactly where it needs to go at a critical inflection point for the field itself. * HARLOTTE BILTEKOFF, ASSOCIATE PROFESSOR OF AMERICAN STUDIES & FOOD SCIENCE AND TECHNOLOGY, UNIVERSITY OF CALIFORNIA, DAVIS, USA *Table of ContentsEditor’s Acknowledgments Permissions Introduction: Why Does Food Matter? Part 1: Revaluing Food in a Global Economy Part 1 Introduction 1. Julie Guthman, “Willing (White) Workers on Organic Farms? Reflections on Volunteer Farm Labor and the Politics of Precarity” 2. Micah Marie Trapp, “Grocery Auction Games: Distribution and Value in the Industrialized Food System” 3. Sarah Besky, “The Labor of Terroir and the Terroir of Labor: Geographical Indication and Darjeeling Tea Plantations” 4. Sandra Fahy, “Famine Talk” 5. David Evans, “Blaming the Consumer – Once Again: The Social and Material Contexts of Everyday Food Waste Practices in Some English Households” 6. Hanna Garth, “Alimentary Dignity: Defining a Decent Meal in Post-Soviet Cuban Household Cooking” Part 2: The Power of Food: From Politics to Microbiopolitics Part 2 Introduction 7. Richard Wilk, “Power at the Table: Food Fights and Happy Meals” 8. Elizabeth Cullen Dunn, “Postsocialist Spores: Disease, Bodies, and the State in the Republic of Georgia” 9. Jakob A. Klein, “Everyday Approaches to Food Safety in Kunming” 10. Melissa L. Caldwell, “Digestive Politics in Russia: Feeling the Sensorium beyond the Palate” 11. Anne Meneley, “Resistance is Fertile!” Part 3: New Bodily Realities in a Techno-Science World Part 3 Introduction 12. Emily Contois, “‘Lose Like a Man’: Gender and the Constraints of Self-Making in Weight Watchers Online” 13. Jessica Hardin, “Everyday Translation: Health Practitioners’ Perspectives on Obesity and Metabolic Disorders in Samoa” 14. Emilia Sanabria, “Sensorial Pedagogies, Hungry Fat Cells and the Limits of Nutritional Health Education” 15. Anna Kirkland, “The Environmental Account of Obesity: A Case for Feminist Skepticism” 16. Aya Hirata Kimura, “Who Defines Babies’ ‘Needs’?: The Scientization of Baby Food in Indonesia” Part 4: More than Human, More than Food Part 4 Introduction 17. Chika Watanabe, “Waste, Incorporated” 18. Anna Tsing, “Arts of Inclusion, or How to Love a Mushroom” 19. Katy Overstreet, “How to Taste Like a Cow: Cultivating Shared Sense in Wisconsin Dairy Worlds” 20. Carl DiSalvo, “Spectacles and Tropes: Speculative Design and Contemporary Food Cultures” Index
£82.50
Bloomsbury Publishing PLC Chinas Porcelain Capital
Book SynopsisMaris Boyd Gillette''s groundbreaking study tells the story of Jingdezhen, China''s porcelain capital, from its origins in 1004 in Song dynasty China to the present day.Gillette explores how Jingdezhen has been affected by state involvement in porcelain production, particularly during the long 20th century. She considers how the Chinese government has consumed, invested in, taxed and managed the local ceramics industry, and the effects of this state intervention on ceramists'' lives, their local environment and the nature of the goods they produce. Gillette traces how Jingdezhen experienced the transition from imperial rule to state ownership under communism, the changing fortunes of the ceramics industry in the early 21st century, the decay and decline that accompanied privatisation, and a revival brought about by an entrepreneurial culture focusing on the manufacture of highly-prized ''art porcelain''.Trade Review[China's Porcelain Capital] is filled with intriguing facts. Those with an interest in porcelain and anyone thinking about working in China, or having artwork made in China, should consider reading this book. * Crafts magazine *Maris Boyd Gillette's book is a welcome addition to the literature on Jingdezhen. It is well sourced and benefits greatly from research in the town and familiarity at first hand with the practical aspects of the industry. * Michael Dillon, The China Quarterly *A comprehensive examination of the ways in which the government of China has controlled, invested in, taxied, managed and consumed the products of the Chinese porcelain industry, especially in the twentieth century. * Ringgold, USA *Historians like to boast of getting their hands dirty in the archives. In this fascinating book, Maris Gillette got her feet muddy to tell the 1000-year story of how the Chinese state, global markets and the potters of Jingdezhen have interacted to produce the most extraordinary porcelains in the world. * Dr Steven Conn, W E Smith Professor of History at Miami University, USA *Positioning ethnographic writing at the center of art historical and anthropological perspectives, Gillette makes an enormous contribution to our understanding of cultural production in China. This astute and intimate portrait uses first-rate scholarship and a unique apprenticeship in the community to reveal the complexities of contemporary ceramic production in Jingdezhen. * Dr Morgan Perkins, Associate Professor of Anthropology and Art at the State University of New York, USA *What a story, the town of Jingdezhen! It began making ceramics over a thousand years ago, produced porcelain for emperors of four dynasties while it made blue-and-white ware famous throughout the world, declined sadly under the Nationalist Republic, revived under Mao’s state socialism, and was abruptly shut down in China’s economic reforms of the 1990s, only to emerge for the third time as a destination for tourists and artists in the 21s century. Maris Gillette tells this story in a clear, fast-moving narrative, completely free of academic jargon, that will appeal to scholarly and popular readers alike. * Dr Stevan Harrell, Professor of Anthropology at the University of Washington, USA *A fascinating read providing an historic and contemporary context of a city in China, whose economic survival and worldwide fame has been uniquely due to a single product, porcelain. For me, involved in education and as an artist potter making work on a regular basis in ‘Jingdezhen’ it was both intriguing in its narrative and hugely informative. * Felicity Aylieff, Head of Programme for Ceramics and Glass at the Royal College of Art, UK *Table of Contents1. The world's most famous ceramics and the people who made them 2. Creating a porcelain capital, prehistory to 1785 3. Decline and disarray, 1786 - 1948 4. Production and politics, 1949 - 1972 5. Dual track porcelain, 1973 - 1993 6. Porcelain capital no more, 1994 - 2010 7. From porcelain capital to heritage site Glossary Bibliography Index
£999.99
Nova Science Publishers Inc Economic Impacts of Foreign-Source Animal Disease
Book SynopsisThis book presents a modelling framework in which epidemiological model results are integrated with an economic model of the U.S. agricultural sector to enable estimation of the economic impacts of outbreaks of foreign-source livestock diseases. To demonstrate the model, the study assessed results of a hypothetical outbreak of foot-and-mouth disease (FMD). The modelling framework includes effects of the FMD episode on all major agricultural products and assesses these effects on aggregate supply, demand, and trade over 16 quarters. Model results show a potential for large trade-related losses for beef, beef cattle, hogs, and pork, though relatively few animals are destroyed. This model is more comprehensive than previous work because it has components for modelling both economic effects and disease-spread effects from an outbreak, for which the results can be integrated. It also assesses the effects of a disease outbreak on major agricultural sectors- livestock and crops- along vertical market chains, from production to consumption. Thirdly, it projects the impact of the disease outbreak over 20 calendar quarters, rather than for just one year.
£47.69
University of Iowa Press Meat Makes People Powerful: A Global History of
Book SynopsisFrom large-scale cattle farming to water pollution, meat— more than any other food—has had an enormous impact on our environment. Historically, Americans have been among the most avid meat-eaters in the world, but long before that meat was not even considered a key ingredient in most civilizations’ diets. Labor historian Wilson Warren, who has studied the meat industry for more than a decade, provides this global history of meat to help us understand how it entered the daily diet, and at what costs and benefits to society.Spanning from the nineteenth century to current and future trends, Warren walks us through the economic theory of food, the discovery of protein, the Japanese eugenics debate around meat, and the environmental impact of livestock, among other topics. Through his comprehensive, multifaceted research, he provides readers with the political, economic, social, and cultural factors behind meat consumption over the last two centuries. With a special focus on East Asia, Meat Makes People Powerful reveals how national governments regulated and oversaw meat production, helping transform virtually vegetarian cultures into major meat consumers at record speed.As more and more Americans pay attention to the sources of the meat they consume, Warren’s compelling study will help them not only better understand the industry, but also make more informed personal choices. Providing an international perspective that will appeal to scholars and nutritionists alike, this timely examination will forever change the way you see the food on your plate.
£64.00
Clanrye International Manufacturing Planning and Logistics Management
Book Synopsis
£88.19
Blurb Gold graphic sir Michael branded Blank page
Book Synopsis
£999.99
Blurb $ir Michael branded Limited edition Manhattan
Book Synopsis
£33.65
Paul White Enterprises Play to Win: 5 Principles to Succeed in Life and
Book Synopsis
£999.99
Guideline Publications Ltd Hawker Siddeley/blackburn Buccaneer: Warpaint Series no 2
£19.01
Guideline Publications Ltd Junkers JU 87 Stuka
£19.01
Guideline Publications Ltd North American F-100 Super Sabre
£19.01
Cadcamcae Works Creo Manufacturing 9.0 Black Book
Book Synopsis
£42.74
Cadcamcae Works Creo Manufacturing 9.0 Black Book (Colored)
Book Synopsis
£54.89
Bloomsbury Publishing PLC Rolls-Royce
Book SynopsisRolls-Royce is one of Britain’s legendary car brands, representing the pinnacle of engineering quality and luxury like no other manufacturer. Since 1904, when Charles Stewart Rolls and Frederick Henry Royce began their collaboration, the Rolls-Royce name has earned respect and admiration the world over. This is the full story of Britain’s premier luxury car-maker, from the early experimental models through the 40/50 Silver Ghost, the Twenty, the Phantoms, the Wraiths and their post-1945 successors, with evocative names such as Silver Shadow and Silver Seraph. It celebrates more than 110 years of car manufacture under the Rolls-Royce brand, revealing how careful management and simple dedication have ensured that the Rolls-Royce name remains a byword for the best of the best.Table of ContentsEarly Days and the Silver Ghost Twenties and Phantoms Transition Clouds and Phantoms Shadows, Spirits and Seraphs German Ownership Further Reading Places to Visit Index
£8.99
David & Charles MG's Abingdon Factory
Book SynopsisThis book is a pictorial study of the workers who built the legendary line of MG sports cars. With over 160 period photos depicting factory life, car building, and the war effort, this is a fascinating story. The demand for these fiery little cars exploded, eventually pushing to a massive facility outside of Abingdon. The factory included everything needed to build the vehicles, as well assoccer and cricket fields, a pool hall, and a hockey rink. The facility even had its own volunteer fire department, it was so well developed. MG Abingdon?s famous racing reputation gained in the 1930s made it the obvious place to site BMC''s Competition department with its maiden venture the 1955 Le Mans 24 hour race. The many original pictures in this book chronicle every aspect of the factory, from its opening amidst great euphoria in 1930 to its closing amidst great recriminations in 1980.Trade ReviewLong-time competitions department employee Brian Moylan, author of Works Rally Mechanic' and Anatomy of the Works Minis', also published by Veloce, wrote the extensive to this book, which comprises an extraordinary collection of pictures of the MG factory throughout its life. Perhaps unsurprisingly, given the author's credentials, the competitions side of the company is given considerably more space, as are its wartime activities with military vehicles and the factory's development and new production methods. This book helps to paint a fine picture of the British motor industry as it once was. – Speedscene.
£15.29
Taylor & Francis Ltd Democratizing Technology: Risk, Responsibility
Book SynopsisDemocratizing Technology provides a much-needed fresh perspective on the regulation of chemicals, and an important contribution to green thinking about technology.Caroline Lucas, Green Party MEP. This book is an excellent critique of the current risk-based approach to technology. By exploring the philosophical underpinnings and the practical applications of current policy on science and technology, Chapman exposes the serious flaws in allowing economic considerations to dominate the agenda in this area. Her proposals for reform are expertly constructed and deserve urgent and serious consideration by policy-makers.Dr Stuart Parkinson, Executive Director, Scientists for Global Responsibility. In this important book Anne Chapman argues that decisions about technology should answer a republican question: what kind of public world should we create through technology? Democratizing Technology deserves to be read widely. John ONeill, Professor of Political Economy, University of Manchester, UK A welcome addition to the new, more empirical and applied literature in philosophy of technology. This book will be essential reading for a variety of scholars and for the general reader intent on understanding, and criticizing, our chemically made world.Andrew Light, Interim Director, Program on the Environment, University of Washington, US What is technology? How do humans use it to build and modify the world? What are the relationships between technology, science, economics and democratic governance? What, if any, are our ethical and political responsibilities and choices in how we develop, deploy and control technology in democratic states? Democratizing Technology sets out to answer these questions. Focusing on the most widespread and pervasive technology - chemicals - this groundbreaking volume peels apart the critical technology debate to look at the relationship between humans, technology and the biological world. Attention is given to the immensely important new regulations, REACH (Registration, Evaluation, Authorization and restriction of Chemicals), the EUs largest ever legal framework, discussing the problems that are likely to occur in REACHs reliance on risk assessment methods and suggesting an alternative way forward for the regulation of chemicals. Providing much-needed clarity and insight into the heart of key debates in science and technology, risk analysis and mitigation, and domestic and international law, this volume arrives as a breath of fresh air.Trade Review'Democratizing Technology is an interesting book with contorversial opinions and proposals. [...] The book is a good candidate for the start of many interesting discussions in and out the classroom. Recommended.' R.E. Buntrock, formerly, University of Maine, USA 'Where the book excels is the thoughtful exploration of questions of profound relevance to public health, such as divergence between our understanding, our behaviours and public policies with respect to risk and responsibility. The analysis provides innovative insights for behaviouralists, policy development in both theoretical and practical spheres, ethicists, political analysts, environmental health scholars and all who encounter technology, and wonder about how we personally and collectively respond to technology in our midst.' Australian and New Zealand Journal of Public Health 'An interesting book with controversial opinions and proposals... Recommended' ChoiceTable of ContentsPreface * Acknowledgements * Introduction * What is Technology? * Technology as World-Building * Technology, Science and the Economy * The Regulation of Chemicals * Risk * Assessing Risks from Chemicals * The Ethical and Political Framework of Regulation * Responsibility * Making Decisions about Technology * Index
£154.56
Taylor & Francis Ltd Deadly Medicines and Organised Crime: How Big
Book SynopsisPRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the pharmaceutical industries and their charade of fraudulent behaviour, both in research and marketing where the morally repugnant disregard for human lives is the norm. He convincingly draws close comparisons with the tobacco conglomerates, revealing the extraordinary truth behind efforts to confuse and distract the public and their politicians. The book addresses, in evidence-based detail, an extraordinary system failure caused by widespread crime, corruption, bribery and impotent drug regulation in need of radical reforms. "The main reason we take so many drugs is that drug companies don't sell drugs, they sell lies about drugs. This is what makes drugs so different from anything else in life...Virtually everything we know about drugs is what the companies have chosen to tell us and our doctors...the reason patients trust their medicine is that they extrapolate the trust they have in their doctors into the medicines they prescribe. The patients don't realise that, although their doctors may know a lot about diseases and human physiology and psychology, they know very, very little about drugs that hasn't been carefully concocted and dressed up by the drug industry...If you don't think the system is out of control, please email me and explain why drugs are the third leading cause of death...If such a hugely lethal epidemic had been caused by a new bacterium or a virus, or even one-hundredth of it, we would have done everything we could to get it under control." FROM THE INTRODUCTIONTable of ContentsForeword by Richard Smith. Foreword by Drummond Rennie. About the author. Introduction. Confessions from an insider. Asthma deaths were caused by asthma inhalers. Shady marketing and research. Organised crime, the business model of big pharma. Hoffman-La Roche, the biggest drug pusher. Hall of Shame for big pharma. The crimes are repetitive. It's organised crime. Very few patients benefit from the drugs they take. Clinical trials, a broken social contract with patients. Conflicts of interest at medical journals. The corruptive influence of easy money. What do thousands of doctors on industry payroll do? Seeding trials. Rent a key opinion leader to 'give advice'. Rent a key opinion leader to 'educate'. Hard sell. Clinical trials are marketing in disguise. Ghostwriting. The marketing machine. Hard sell ad nauseam. Highly expensive drugs. Excesses in hypertension. Patient organisations. NovoSeven for bleeding soldiers. Impotent drug regulation. Conflicts of interest at drug agencies. Corruption at drug agencies. The unbearable lightness of politicians. Drug regulation builds on trust. Inadequate testing of new drugs. Too many warnings and too many drugs. Public access to data at drug agencies. Our breakthrough at the EMA in 2010. Access to data at other drug agencies. Deadly slimming pills. Neurontin, an epilepsy drug for everything. Merck, where the patients die first. Fraudulent celecoxib trial and other lies. Marketing is harmful. Switching cheap drugs into expensive ones in the same patients. Novo Nordisk switches patients to expensive insulin. Astra-Zeneca switches patients to expensive me-again omeprazole. Blood glucose was fine but the patients died. Novo Nordisk interferes with an academic publication. Psychiatry, the drug industry's paradise. Are we all crazy or what? Psychiatrists as drug pushers. The chemical imbalance hoax. Screening for psychiatric disorders. Unhappy pills. Prozac, a terrible Eli Lilly drug turned into a blockbuster. Exercise is a good intervention. Further lies about happy pills. Pushing children into suicide with happy pills. Glaxo study 329. Concealing suicides and suicide attempts in clinical trials. Lundbeck's evergreening of citalopram. Antipsychotic drugs. Zyprexa, another terrible Eli Lilly drug turned into a blockbuster. The bottomline of psychotropic drugs. Intimidation and threats to protect sales. Busting the industry myths. General system failure calls for a revolution. Our drugs kill us. How much medicine do we really need and at what cost? For-profit is the wrong model. Clinical trials. Drug regulatory agencies. Drug formulary and guideline committees. Drug marketing. Doctors and their organisations. Patients and their organisations. Medical journals. Journalists. Having the last laugh at big pharma. Money don't smell. Creating diseases. Index.
£35.99
Nawcc Pillar & Scroll
Book Synopsis
£31.82
Nawcc Antebellum Shelf Clock Making in Farmington and
Book Synopsis
£26.59
Rupa Publications India Pvt Ltd. Bringing the Rainbow: The Hindware Story
Book SynopsisIn Bringing the Rainbow,eading industrialist R.K Somany tells the story of how he pioneered a whole new industry (and its practices) and built the country''s best known sanitaryware brand, Hindware.The years immediately preceding and following Independence saw manyeading Marwari mercantile families in Kolkataincluding the Somany familyspread their wings into industry. In the 1960s, when the Somany family decided to build India''s first vitreous ceramic sanitaryware plant in Punjab, R.K. Somany, then in his early to mid-twenties, was put in charge of building the factory and running the company. This is an engaging and impactful account of R.K. Somany''s HSIL going from rank novice to marketeader.Even though Hindware is a household name today, Somany had to overcome numerous obstacles: the anti-enterprise attitude in India''s socialist era; the harassment he had to endure during the Emergency; his principled stand against his products being sold in the black market; facing fierce opposition for printing the maximum retail price on all his products; and his decision to terminate the services of dealers who sold Hindware products above MRP. The dogged fighter in R.K. Somany also came to the fore when he fought and won both major battles and minor skirmishes against I.K Gujaral, former Prime Minister of India; Bansial, former Chief Minister of Haryana; and two of his own brothers.In many ways, Somany''s phenomenal rise is a proxy for India''s post-Independence industrialisation drive. Bringing the Rainbow, which is filled with many professional and personal anecdotes, will thus be of interest to both the student of Indian business history as well as those whoove a good story well told.
£20.89
Nova Science Publishers, Inc. The New Geography in the Global Automotive Industry
Book SynopsisThis book is a valuable contribution for all those interested in the functioning of the historical geography of capitalism. As sociology has been emphasizing for some years now, throughout the 20th century, capital has perfected its mobility capacity, subjecting communities, workers and territories, increasingly susceptible to locational blackmail, that is, to the constant threat of plant closures. This process is due, for example, to union pressure and the reluctance of other agents to ensure production stability. As these plants adopt increasingly modern practices, characterized by highly compact industrial organization models such as Completely Knock-Down (CKD) and its prefabricated and imported kits, the attachment of these companies to their locations weakens. Consequently, the trend of investment becomes more frequent. This book accurately identifies these movements, above all, in terms of Foreign Direct Investments (FDIs), which flood countries and regions lacking indigenous automobile groups and transform them into low-cost production and export platforms.
£65.69
The University of Chicago Press Genentech
Book SynopsisIn the fall of 1980, Genentech, Inc, a little-known California genetic engineering company, became the overnight darling of Wall Street, raising $38 million in its initial public stock offering. This title provides portraits of the people significant to Genentech's science and business, and focuses on how personality affects the growth of science.Trade Review"Sally Smith Hughes has crafted an engaging historical account of Genentech from its beginnings as a small laboratory at the University of California, San Francisco to the 2009 merger with Roche for $47 billion.... Her account will appeal to a broad audience and is a must read for scholars interested in the history of biotechnology. Highly recommended." (Choice)"
£16.00
The University of Chicago Press Building Natures Market The Business and
Book Synopsis
£31.00
The University of Chicago Press Tight Knit Global Families and the Social Life of
Book SynopsisThe coveted Made in Italy label calls to mind visions of nimble-fingered Italian tailors lovingly sewing elegant, high-end clothing. The phrase evokes a sense of authenticity, heritage, and rustic charm. Yet, as ElizabethL. Krause uncovers in Tight Knit, Chinese migrants are the ones sewing Made in Italy labels into low-cost items for a thriving fast-fashion industryall the while adding new patterns to the social fabric of Italy's iconic industry. Krause offers a revelatory look into how families involved in the fashion industry are coping with globalization based on longterm research in Prato, the historic hub of textile productionin the heart of metropolitan Tuscany. She brings to the fore the tensionsover value, money, beauty, family, care, and belongingthat are reaching a boiling point as the country struggles to deal with the same migration pressures that are triggering backlash all over Europe and North America. Tight Knit tells a fascinating story about the heterogeneity of
£24.00
The University of Chicago Press Outbreak
Book SynopsisTrade Review"A remarkable sweeping overview and evaluation of food safety practices that well serves both experts working in the field and members of the general public interested in the problem of food safety. Lytton shows how major outbreaks have prompted a variety of changes to reduce the risk of foodborne illness. Yet, as he argues persuasively, we don't have firm scientific knowledge as to the degree to which--if at all--most of these measures have actually achieved their goal."-- (01/02/2019) "From swill milk to HACCP to FSMA to Blockchain, Lytton weaves a compelling biological story of how we feed ourselves and the interplay between the supply chain, regulation, media, and civil litigation."--William D. Marler, Esq., The Food Safety Law Firm "In Outbreak, Lytton gives us a legal scholar's superb analysis of how government, lawyers, and civil society are struggling to prevent the tragic and unnecessary illnesses, hospitalizations, and deaths caused by microbial food contaminants. Foodborne illness may seem like an intractable problem, but Lytton's suggestions for dealing with it are well worth attention, as is everything else in this beautifully written, thoughtful, and readable account. I couldn't put it down." -- (01/02/2019)
£26.00
The University of Chicago Press A Rainbow Palate
Book SynopsisTrade Review"Elegant and insightful. . . . What is stunning is how pertinent the book is to our own times. You will find here a rehearsal for everything we are facing today—the fads, the fears, the government interventions that are either too late or too rushed, and the nagging sense that the food that most delights the eye may not always be the food that serves us best." * Times Literary Supplement *"Cobbold has produced a fascinating account and analysis of how these dyes were introduced, contested, and ultimately legitimized in an emerging globalized industrial food system. . . . What Cobbold draws our attention to is the inevitable negotiation around expertise and the permitted uses of novel chemical additives. In doing so, she enters a larger discussion about how novel scientific objects and processes evade control once they emerge from the laboratory and enter the world where they are unexpectedly transformed and used. More broadly, this book helps historicize the public construction of trust in science and chemistry." * Scientia Canadensis *"There are many reasons that Cobbold’s story is compelling. Her research is detailed and extensive, using many archival sources along with other primary and secondary ones. She also makes good use of the scientific and mainstream press, juxtaposing the opinions of chemists, government policymakers, and consumers. Lengthy excerpts from press articles, in particular, convey the flavor of shifting public discourse. A Rainbow Palate is also compelling due to Cobbold’s clear writing, accessible to those with little background in chemical history; the book is punctuated by helpful signposts summarizing and linking sections together. . . . Cobbold’s insights about the 19th century help us to understand why this system of trust has become frayed in the 21st century." * H-Soz-Kult *"A pioneering work of food science, this compact, well-referenced book captures the rise and fall of the use of synthetic chemicals—particularly coal tar dyes—which were employed in food coloring in the US and Europe during the late 19th and early 20th centuries. . . . The book would be a good acquisition for academic and special collections that support food history, food science, and history of chemistry programs. . . . Recommended." * Choice *"A Rainbow Palate fits into a growing body of literature that attempts to bridge the history of modern chemistry to that of food consumption. . . . Cobbold's distinctive contributions to this scholarship become apparent from her deep research into the history of coal tar dyes, revealing the ways in which a profit-driven commitment to the discovery of new synthetic chemicals and their corresponding consumer markets encouraged the inclusion of textile dyes in food." * Technology and Culture *"[Cobbold] highlights a dichotomy between the intimacy we have with our diet and the gulf that often separates us from the understanding of where our ingredients come from." * Nature Reviews Chemistry *"If you thought food coloring was not a serious subject in the history of science, this engaging and accessible book will show you very quickly just how wrong you were. Cobbold tells a wonderful story of complex and fascinating mutual interactions of science, commerce, industry, government, journalism, and law, about how powerful interests jostled around the use and regulation of potentially hazardous synthetic chemical dyes in food. This is a neglected aspect of the celebrated developments in organic chemistry and the dyestuffs industry in the late nineteenth century. In Cobbold’s detailed account, reaching across several countries, we witness how political and legal systems were at a loss to know how to manage and regulate the impact of a formidable and fast-moving field of science, while scientific experts found themselves unable to control the use of their creations or the narratives told about them. A Rainbow Palate is an illuminating cautionary tale of how an important unintended consequence of cutting-edge science can work itself into the very fabric of our daily lives without a clear plan on anyone’s part." -- Hasok Chang, University of Cambridge"In this timely book, Cobbold tells the remarkable story of how the first industrially produced chemical food dyes were created and adjudicated as legitimate additives to food. Nineteenth- and twentieth-century chemists, manufacturers, legislators, and the public all wrestled with questions around food additives still highly relevant today, concerning risk, health, public safety, regulation, testing, and the environment. Were food colorings brilliant instances of scientific and industrial progress or toxic and unnatural artifices? How could dangers be detected and who could keep the public safe? Faced with uncertainty, how should people trust what they ate? Lively and significant, A Rainbow Palate will be indispensable for anyone interested in the difficult process by which societies manage, and fail to manage, radical new technoscientific entities." -- Simon Werrett, author of Thrifty ScienceTable of ContentsPreface Introduction 1 Food adulteration and the rise of the food chemist 2 The wonder of coal tar dyes 3 From dye manufacturer to food manufacturer 4 The struggle to devise tests to detect dyes and assess their toxicity 5 The appointment of public food analysts in Britain 6 How British food chemists responded to the use of coal tar dyes 7 French and German chemists seek to arbitrate the use of synthetic chemicals in food 8 The US government acts against chemical dyes in food Conclusion Acknowledgments Notes Bibliography Index
£33.25
Columbia University Press Garden Variety The American Tomato from
Book SynopsisJohn Hoenig explores the path by which the tomato went from a rare seasonal crop to America’s favorite vegetable. Garden Variety illuminates American culinary culture from 1800 to the present, challenging a simple story of mass-produced homogeneity and demonstrating the persistence of diverse food cultures throughout modern America.Trade ReviewA well-written book that demonstrates that the story of industrial food may not be nearly as linear or as top-down as we have thought. -- James McWilliams, Texas State UniversityTable of ContentsAcknowledgmentsIntroduction1. The Early American Tomato2. The Tomato on the Farm: Culinary and Agricultural Advancements, 1820–19003. A Tomato for All Seasons: The Development of the Twelve-Month Fresh and Processed Tomato Industries, 1880–19454. Consuming Tomatoes: Culinary Creativity and Expansion in the Age of Industrialization5. “A Poor Tomato Is Better Than No Tomato”: The Harvester and the Commodification of the Tomato6. Meet the Farmer or Become One: Challenging Commercial Food CultureConclusionNotesBibliographyIndex
£27.00
University of Illinois Press Disruption in Detroit
Book SynopsisTrade ReviewChoice Outstanding Academic Title, 2019 "Disruption in Detroit should take its place near the top of this reading list. Clark masterfully details the struggles of autoworkers who faced economic upheaval at the core of the midcentury industrial economy." --Labor Studies in Working-Class History"Exposes the myth of the prosperous postwar auto worker and deftly deals with the delicate interplay among larger national economic forces, auto industry and auto union policies, and the lives of those who labored and lived in the Motor City in the decade and a half after World War II."--Stephen Meyer, author of Manhood on the Line: Working Class Masculinities in the American Heartland"Well-written and well-researched, this book challenges and transforms the way we understand the immediate postwar era. Daniel Clark closely examines auto work and ordinary autoworkers, people whose lives have been overwhelmed by the narrative of postwar economic expansion and overlooked by most scholars. The vaunted economic boom was not the vehicle for the making of the Detroit middle class, Clark shows. Detroit autoworkers and their families experienced the same job instability and economic insecurity that had long shaped working-class life and labor. Attentive to gender and race, Clark offers an astute and cogent argument informed by wide and deep research in newspapers and close listening to and reading of oral histories. Providing a startling different perspective on the postwar boom and the alleged heyday of the United Auto Workers when high wages and benefits pushed autoworkers into the middle class, the book requires revision of modern American history as well as midcentury labor history."--Nancy Gabin, author of Feminism in the Labor Movement: Women and the United Auto Workers, 1935-1970"Disruption in Detroit breaks ground for exciting new research questions and debates in this crucial period of working-class history. Clark's work should prompt historians of the United States, Canada, and beyond to rethink and re-examine post-war working-class lives." --Labour/Le Travail"Its careful consideration of large economic trends balanced with personal interviews provides readers with a good portrait of the actual struggles of what some have (perhaps mistakenly) called the 'aristocracy of American labor.'" --The Michigan Historical Review"Essential." --Choice"Disruption in Detroit should take its place near the top of this reading list. Clark masterfully details the struggles of autoworkers who faced economic upheaval at the core of the midcentury industrial economy." --Labor Studies in Working-Class History
£77.35
University of Illinois Press Disruption in Detroit
Book SynopsisIt is a bedrock American belief: the 1950s were a golden age of prosperity for autoworkers. Flush with high wages and enjoying the benefits of generous union contracts, these workers became the backbone of a thriving blue-collar middle class. It is also a myth. Daniel J. Clark began by interviewing dozens of former autoworkers in the Detroit area and found a different story--one of economic insecurity caused by frequent layoffs, unrealized contract provisions, and indispensable second jobs. Disruption in Detroit is a vivid portrait of workers and an industry that experienced anything but stable prosperity. As Clark reveals, the myths--whether of rising incomes or hard-nosed union bargaining success--came later. In the 1950s, ordinary autoworkers, union leaders, and auto company executives recognized that although jobs in their industry paid high wages, they were far from steady and often impossible to find.Trade ReviewChoice Outstanding Academic Title, 2019 "Disruption in Detroit should take its place near the top of this reading list. Clark masterfully details the struggles of autoworkers who faced economic upheaval at the core of the midcentury industrial economy." --Labor Studies in Working-Class History"Exposes the myth of the prosperous postwar auto worker and deftly deals with the delicate interplay among larger national economic forces, auto industry and auto union policies, and the lives of those who labored and lived in the Motor City in the decade and a half after World War II."--Stephen Meyer, author of Manhood on the Line: Working Class Masculinities in the American Heartland"Well-written and well-researched, this book challenges and transforms the way we understand the immediate postwar era. Daniel Clark closely examines auto work and ordinary autoworkers, people whose lives have been overwhelmed by the narrative of postwar economic expansion and overlooked by most scholars. The vaunted economic boom was not the vehicle for the making of the Detroit middle class, Clark shows. Detroit autoworkers and their families experienced the same job instability and economic insecurity that had long shaped working-class life and labor. Attentive to gender and race, Clark offers an astute and cogent argument informed by wide and deep research in newspapers and close listening to and reading of oral histories. Providing a startling different perspective on the postwar boom and the alleged heyday of the United Auto Workers when high wages and benefits pushed autoworkers into the middle class, the book requires revision of modern American history as well as midcentury labor history."--Nancy Gabin, author of Feminism in the Labor Movement: Women and the United Auto Workers, 1935-1970"Disruption in Detroit breaks ground for exciting new research questions and debates in this crucial period of working-class history. Clark's work should prompt historians of the United States, Canada, and beyond to rethink and re-examine post-war working-class lives." --Labour/Le Travail"Its careful consideration of large economic trends balanced with personal interviews provides readers with a good portrait of the actual struggles of what some have (perhaps mistakenly) called the 'aristocracy of American labor.'" --The Michigan Historical Review"Essential." --Choice"Disruption in Detroit should take its place near the top of this reading list. Clark masterfully details the struggles of autoworkers who faced economic upheaval at the core of the midcentury industrial economy." --Labor Studies in Working-Class History
£20.89
Yale University Press The Cutter Incident
Book SynopsisVaccines have saved more lives than any other single medical advance. This book recounts a devastating episode in 1955 at Cutter Laboratories in Berkeley, California, that has led many pharmaceutical companies to abandon vaccine manufacture. It offers a full account of the Cutter disaster.Trade Review"Offit . . . has written a fascinating and highly readable account of the development of the polio vaccine. He also offers a compelling plea for a strengthened law to provide relief to companies that produce vaccines so that our nation may be afforded the most cost-effective and long-lasting form of prevention against many infectious diseases—an effective vaccine."—Stanley Goldfarb, New York Post"The best account you will ever read about the interplay between big drug companies and bigger government."—Peter Huber, Forbes"The book is very well written and reads almost like a detective story, with a nice balance between personal anecdotes and new materials not discussed in other accounts of the Cutter incident. It draws on meticulous archival documentation and on interviews with public health officers, pharmaceutical company executives, Cutter employees, and victims of the partially inactivated vaccine. . . . An important and valuable contribution."—Nadav Davidovitch, Isis"The Cutter Incident is an enjoyable read, at times like a detective thriller, at others like a courtroom drama."—Jonathan R. Carapetis, The British Medical Journal"Offit describes the development of polio vaccine, from trials of early vaccines through to the appearance on the scene of Jonas Salk. . . . The Cutter Incident is an enjoyable read, at times like a detective thriller; at other times like a courtroom drama. . . . [The book] reminds us how close we have been and indeed still are—to losing immunization as our most effective public health tool."—Jonathan R. Carapetis, British Medical Journal"What is causing the shortage of desperately needed vaccines to combat pneumonia, tetanus, chicken pox, measles, mumps and influenza? Why is an effective vaccine for Lyme disease no longer on the market? And what are the consequences for our children? Dr. Paul Offit confronts these vital questions in The Cutter Incident, a brilliant piece of writing about a medical tragedy, exactly fifty years ago, that revolutionized the development and testing of vaccines in the United States, while forever changing the legal culture that had once kept punitive lawsuits under control. Offit’s remarkable book is certain to become a fixture in the increasingly angry battle over the impact of medical liability on the effective treatment of disease."—David M. Oshinsky, author of Polio: An American Story “Dr. Offit brings us into the entangled world of medicine and law. Readers will have a better understanding of the impact that legal suits have on the vaccine industry, investment, and decisions not to pursue lifesaving vaccines because of liability issues.”—Dean Mason, President and CEO, Sabine Vaccine Institute"One of the best overviews of vaccines from the vantage of events associated with vaccine safety during an earlier era that I have ever read."—Maurice Hilleman, Merck Institute for Vaccinology“This book not only brings to life the main actors involved, it also demonstrates how this incident created legal precedents that forever changed product liability laws.”—Roland Sutter, World Health Organization
£25.00
Yale University Press The New Industrial Revolution Consumers Globalization and the End of Mass Production
Book SynopsisThe rapid emergence of China and India as prime locations for low-cost manufacturing has led some analysts to conclude that manufacturers in the old economies - the US, UK, Germany, and Japan - are being edged out of a profitable future. This book explores 250 years in the history of manufacturing.Trade Review"Highly readable and engaging, liberally peppered with anecdotes that convey both Marsh's knowledge of the very human nature of industry… The New Industrial Revolution will be a valuable read for anyone who wants to understand the role of manufacturing." —Bryan Betts, Engineering and Technology -- Engineering and Technology * Bryan Betts *"Marsh's book takes us back to basics, and looks at the challenges raised by re-industrialisation… A must-read."—Global Journal * Global Journal *"What is so useful about Marsh's contribution in the New Industrial Revolution is that he has made an objective assessment of the evidence. And there are few people in Britain who are better equipped to do so."—Evan Davis, Financial Times -- Evan Davis * Financial Times *
£19.49
John Wiley & Sons Inc Human Factors Methods for Improving Performance
Book SynopsisHuman Factors Methods for Improving Performance in the Process Industries provides guidance for managers and plant engineering staff on specific, practical techniques and tools for addressing forty different human factors issues impacting process safety.Table of ContentsPreface xi Acknowledgments xiii Abbreviations and Acronyms xv 1 Introduction 1 1.1 Purpose of This Book 1 1.2 Human Factors 1 1.3 Human Error 3 1.4 Structure of This Book 5 1.5 Linkage to Other CCPS Publications 6 1.6 References 7 2 The Case for Human Factors 9 2.1 Why is Human Factors Needed? 9 2.2 Past Incidents 11 2.3 Business Value/Justification 11 2.4 Human Factors in the Life Cycle of a Chemical Plant 16 2.5 Needs Driven Program 17 2.6 References 19 3 Performance Measurement and Improvements 21 3.1 Building Improvements into Existing Systems 21 3.2 Measures of Performance 22 3.3 Roles and Responsibilities 24 3.4 Continuous Improvement 25 3.5 References 28 HUMAN FACTORS TOOL KIT Facilities and Equipment 4 Process Equipment Design 31 4.1 Introduction 31 4.2 Tools 33 4.3 References 33 4.4 Additional References 34 5 Process Control Systems 37 5.1 Introduction 37 5.2 Issues/Example 37 5.3 Tools 39 5.4 Additional References 39 6 Control Center Design 41 6.1 Introduction 41 6.2 Tools 42 6.3 References 43 6.4 Additional References 43 7 Remote Operations 45 7.1 Introduction 45 7.2 Tools 47 7.3 Reference 48 8 Facilities and Workstation Design 49 8.1 Introduction 49 8.2 Tools 53 8.3 References 55 8.4 Additional References 55 9 Human/Computer Interface 57 9.1 Introduction 57 9.2 Human Interactions with Control System Software 58 9.3 Tools 59 9.4 References 63 9.5 Additional References 64 10 Safe Havens 67 10.1 Introduction 67 10.2 Human Factors Issues 68 10.3 Tools 70 10.4 References 70 11 Labeling 71 11.1 Introduction 71 11.2 Tools 72 11.3 References 74 People 12 Training 77 12.1 Introduction 77 12.2 Guidelines for Training Programs 77 12.3 Guidelines for Designing and Delivering Training 78 12 4 Tools 81 12.5 References 81 13 Communications 83 13.1 Introduction 83 13.2 Issues/Examples 83 13.3 Tools 85 13.4 References 85 14 Documentation Design and Use 87 14.1 Introduction 87 14.2 Converting to Electronic Documentation 88 14.3 Use of Documents 90 14.4 Tools 92 14.5 References 93 14.6 Additional References 94 15 Environmental Factors 95 15.1 Introduction 95 15.2 Noise 95 15.3 Vibration 96 15.4 Temperature and Relative Humidity 99 15.5 Air Quality 101 15.6 Lighting 102 15.7 References 105 16 Workloads and Staffing Levels 107 16.1 Introduction 107 16.2 Issues/Examples 107 16.3 Tools 108 16.4 References 109 17 Shiftwork Issues 111 17.1 Introduction 111 17.2 Tools 112 17.3 References 114 17.4 Additional References 114 18 Manual Materials Handling 117 18.1 Introduction 117 18.2 Manual Materials Handling Guidelines 118 18.3 References 121 18.3 Additional References 122 Management Systems 19 Safety Culture 125 19.1 Introduction 125 19.2 What is Safety Culture? 125 19.3 Tools 127 19.4 Safety Culture: A Process Industry Case Study 130 19.5 Benefits 131 19.6 References 131 19.7 Additional References 132 20 Behavior Based Safety 133 20.1 Introduction 133 20.2 Tools 134 20.3 Expected Results 137 20.4 References 137 20.5 Additional References 138 21 Project Planning, Design, and Execution 139 21.1 Introduction 139 21.2 Human Factors Tools for Project Management 139 21.3 References 143 22 Procedures 145 22.1 Introduction 145 22.2 Tools 146 22.3 References 151 22.4 Additional References 151 23 Maintenance 153 23.1 Introduction 153 23.2 Identifying Critical Maintenance Tasks 153 23.3 Maintenance Protocol 154 23.4 Tools 155 23.5 References 156 24 Safe Work Practices and Permit-to-Work Systems 159 24.1 Introduction 159 24.2 Issues 159 24.3 Tools 163 24.4 References 164 24.5 Additional Reference 164 25 Management of Change 165 25.1 Introduction 165 25.2 Tools 167 25.3 References 172 26 Qualitative Hazard Analysis 175 26.1 Introduction 175 26.2 Tools—Human Failures 176 26.3 Tools—Human Factors 177 26.4 References 179 26.5 Additional References 180 27 Quantitative Risk Assessment 181 27.1 Introduction 181 27.2 Tools 183 27.3 References 184 27.4 Additional References 184 28 Safety Systems 185 28.1 Introduction 185 28.2 People and Safety Systems 185 28.3 Bypassing and Disabling Safety Systems 185 28.4 Shutdown Systems 188 28.5 Selection of Safety Systems 189 28.6 Common Cause Failures in Safety Systems 189 28.7 Tools 190 28.8 References 190 29 Competence Management 191 29.1 Introduction 191 29.2 Elements of Competence Management 193 29.3 Tools 196 29.4 References 197 29.5 Additional References 197 30 Emergency Preparedness and Response 199 30.1 Introduction 199 30.2 Tools 199 30.3 Reference 202 30.4 Additional References 202 31 Incident Investigation 203 31.1 Introduction 203 31.2 Issues/Examples 203 31.3 Tools 205 31.4 References 205 Appendix. Human Factors Checklist 207 Index 225
£116.96
John Wiley & Sons Inc Predictive Approaches in Drug Discovery and
Book SynopsisPractical Utility of Biomarkers in Drug Discovery and Development covers all aspects of biomarker research applied to drug discovery and development and contains state-of-the-art appraisals on the practical utility of genomic, biochemical, and protein biomarkers. Case histories and lessons from successful and unsuccessful applications of biomarkers are included along with key chapters on GLP validation, safety biomarkers and proteomics biomarkers. Regulatory agency perspectives and initiatives both in the US and internationally are also discussed.Trade Review“The ability to correlate in vitro and in vivo biomarker information in the process of drug discovery and development lies at the heart of translational research. The goal is to rapidly translate basic discoveries into clinical applications. This book provides state-of-the-art information on this exciting new research approach.” (Doody’s, 8 February 2013) “The text is packed with interesting, comprehensive, and pertinent information, clearly presented with salient points reinforced by inclusion in text boxes . . . This is an admirable textbook for those dealing with drug discovery and development. I enjoyed reading through it and I would recommend it to anyone who has an interest, or is developing an interest, in the field of biomarkers and their, as yet, unfulfilled potential.” (ISSX International Society for the Study of Xenobiotics, 1 December 2012)Table of ContentsPreface xi Acknowledgments xiii Contributors xv Part I Biomarkers in Drug Discovery 1 1 The Importance of Biomarkers in Translational Medicine 3 Joseph C. Fleishaker 2 Validation of Biochemical Biomarker Assays used in Drug Discovery and Development: A Review ofChallenges and Solutions 23 Gabriella Szekely-Klepser and Scott Fountain 3 Proteomic Methods to Develop Protein Biomarkers 49 Ruth A. VanBogelen and Diane Alessi 4 Overview of Metabolomics Basics 79 Qiuwei Xu and William H. Schaefer Part II Clinical Application of Biomarkers 139 5 Vascular Biomarkers and Imaging Studies 141 Karin Potthoff, Ulrike Fiedler, and Joachim Drevs 6 Cardiovascular Biomarkers as Examples of Success and Failure in Predicting Safety in Humans 163 Simon Authier, Michael K. Pugsley, Eric Troncy, and Michael J. Curtis 7 The Use of Molecular Imaging for Receptor Occupancy Decision Making in Drug Development 189 Ralph Paul Maguire 8 Biosensors for Clinical Biomarkers 203 Sara Tombelli and Marco Mascini Part III Regulatory Perspectives 229 9 Regulatory Perspectives on Biomarker Development 231 Rajanikanth Madabushi, Lawrence Lesko, and Janet Woodcock 10 Perspectives from the European Regulatory Authorities 255 Ian Hudson 11 Use of Biomarker in Drug Development—Japanese Perspectives 269 Yoshiaki Uyama, Akihiro Ishiguro, Harumasa Nakamura, and Satoshi Toyoshima Part IV Predicting in Vivo 289 12 In Vitro–In Vivo Correlations of Hepatic Drug Clearance 291 R. Scott Obach 13 The Potential of In Silico and In Vitro Approaches to Predict In Vivo Drug–Drug Interactions and ADMET/TOX Properties 307 Kenneth Bachmann and Sean Ekins 14 In Vitro–In Vivo Correlations in Drug Discovery and Development: Concepts and Applications inToxicology 331 Rex Denton, Kimberly Brannen, and Bruce D. Car 15 Assessing the Potential for Induction of Cytochrome P450 Enzymes and Predicting the In Vivo Response 353 Jiunn H. Lin Index 383
£117.85
John Wiley & Sons Inc Fisher Investments on Materials
Book SynopsisThe second installment of the Fisher Investments On series is a comprehensive guide to the Materials sector. Fisher Investments on Materials can benefit both new and seasoned investors, covering everything from Materials sector basics to specific industry insights to practical investing tactics, including common pitfalls to avoid.Table of ContentsForeword ix Preface xi Acknowledgments xv Part I Getting Started in Materials 1 Chapter 1 Materials Basics 3 Materials 101 4 Commodity Pricing Basics 9 The Production Process 13 Chapter 2 A Brief History of Materials 29 The Industrial Revolution 29 Structural Shifts in Metals Since the Industrial Revolution 33 Industrialization of the Emerging Markets 37 Chapter 3 Materials Sector Drivers 41 Key Drivers 42 Drivers at Work 46 Case Study: Copper 51 Part II Next Steps: Materials Details 63 Chapter 4 Materials Sector Breakdown 65 Global Industry Classification Standard (GICS) 66 Global Materials Benchmarks 67 Metals & Mining Industry 74 Chemicals 88 Construction Materials 96 Paper & Forest Products 96 Containers & Packaging 98 Chapter 5 Staying Current: Tracking Sector Fundamentals 101 What to Watch 102 Chapter 6 Case Study: The 2003 to 2007 Bull Market in Materials 117 The Backdrop 119 Demand Growth 120 Supply Constraints 130 The Growth of Mergers and Acquisitions 136 Part III Thinking Like a Portfolio Manager 139 Chapter 7 The Top-Down Method 141 Investing is a Science 141 The Top-Down Method 144 Top-Down Deconstructed 150 Managing Against a Materials Benchmark 157 Chapter 8 Security Analysis 163 Make Your Selection 164 A Five-Step Process 165 Important Questions to Ask 173 Chapter 9 Materialize Your Portfolio: Investing Strategies 181 Strategy 1: Adding Value at the Industry and Sub-industry Level 182 Strategy 2: Adding Value at the Security Level 189 Strategy 3: Adding Value in a Materials Sector Downturn 190 Strategy 4: Investing in Commodities 191 Appendix A: Materials Sector Resources 195 Appendix B: Top 10 Materials Firms by Industry 199 Notes 203 Glossary 217 About the Authors 223 Index 225
£18.90
John Wiley & Sons Inc Drug Truths
Book SynopsisThis book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider''s account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.Trade Review?This book, a concise and reasonably priced text, is a must-read for anyone working in the pharmaceutical industry. However, it is not just written for scientist, anyone interested in learning more about the big issues facing pharmaceutical research and development and global healthcare today should find this book thought-provoking.? (Pharmaceutical Journal, September 2009) ?Drug Truths: Dispelling the Myths About Pharma R & D is an generally persuasive argument for the soul of the pharmaceutical industry.? (Journal of Clinical Research Best Practices, December 2009) "I would recommend this book." (Chemistry World, June 2009) "LaMattina stands out from many of the other observers of the industry." (Nature Chemistry, May 2009) "The book provides unique insights into how big pharma manages its R&D. It also serves as a reminder of the useful role the drug industry play in keeping us healthy." (Chemical & Engineering News, April 20, 2009) ?The book offers an insider?s account of the reality of the drug discovery process?revealing it to be more risky, complicated and expensive than many critics suggest. Chapter by chapter, LaMattina addresses the common misconceptions about the pharmaceutical industry?setting the record straight.? (Kansas City InfoZine, February 2009) ?Along with a careful dissection of each false claim and a presentation of the overwhelming evidence that disproves it, LaMattina offers fascinating explanations of the way drug development and government approval function ? relying not on clever rhetoric, but on scientific fact and reliable evidence to support his claims; all the while remaining realistic about the industry's limitations.? (Medical News Today, February 2009) "It's obvious from reading his book that LaMattina believes in his industry, in Big Pharma, and in the research and development that has led to drugs that have cured infectious diseases, delayed encroaching heart disease, controlled arthritis?for many millions?reduced pain and suffering." (TheDay.com, January 25, 2009)Table of ContentsACKNOWLEDGMENTS ix INTRODUCTION xi PART I A MATTER OF THE HEART 1 CHAPTER 1 CHOLESTEROL DRUGS ARE UNNECESSARY 3 CHAPTER 2 INDUSTRY IS MORE INTERESTED IN "ME-TOO" DRUGS THAN IN INNOVATION 13 CHAPTER 3 IT TAKES INDUSTRY TOO LONG TO DISCOVER NEW DRUGS 23 PART II THE ROLE OF PHARMACEUTICAL R&D IN HEALTH CARE 39 CHAPTER 4 DRUGS ARE DISCOVERED BY ACADEMIA 41 CHAPTER 5 NEW MEDICINES ADD COSTS BUT LITTLE BENEFIT 50 CHAPTER 6 BIG PHARMA HAS FAILED AND SHOULD LEARN FROM BIOTECH SUCCESS 59 PART III THE PROFIT MOTIVE 69 CHAPTER 7 THE INDUSTRY INVENTS DISEASES 71 CHAPTER 8 NEW DRUGS ARE LESS SAFE THAN TRADITIONAL MEDICINES 79 CHAPTER 9 INDUSTRY SPENDS MORE ON ADVERTISING THAN ON R&D 91 CHAPTER 10 INDUSTRY DOES NOT CARE ABOUT DISEASES OF THE DEVELOPING WORLD 100 PART IV THE FUTURE 109 CHAPTER 11 BIG PHARMA'S DAY HAS PASSED 111 CHAPTER 12 FINAL REFLECTIONS 122 REFERENCES 124 INDEX 133
£23.76
John Wiley & Sons Inc Fisher Investments on Technology
Book SynopsisThe definitive guide to investing in today's global technology sector The fifth installment of the Fisher Investments on series is an all-encompassing guide to understanding and analyzing investment opportunities within the global Technology sector.Table of ContentsForeword ix Preface xi Acknowledgments xv Part I Getting Started in Technology 1 Chapter 1 Technology Basics 3 More Than Gadgets A Means 4 Technology 101 7 Starting Small: Semiconductors 7 Getting Larger: Products and Components 12 Making It All Work: Software and Services 20 Chapter 2 A Brief History of Modern Technology 25 The Snowball Event: History of Semiconductors 26 History of Computers 31 History of Communications 35 History of the Internet 37 Chapter 3 Technology Sector Drivers 43 Economic Drivers 43 Political Drivers 57 Sentiment Drivers 61 Part II Next Steps: Technology Details 67 Chapter 4 Technology Sector Breakdown 69 Global Industry Classification Standard (GICS) 69 Global Technology Benchmarks 71 Technology Industry Breakdown 75 Chapter 5 Challenges in the Information Technology Sector 99 Product Maturity and Obsolescence 99 Fighting Maturity and Obsolescence 101 Extreme Fluctuations in Supply and Demand 110 Intellectual Property Threats 113 Chapter 6 A Deeper Look at Current and Emerging Technologies 117 Semiconductor Production Process 118 Emerging Manufacturing Technologies 122 Computer Technology 124 Part III Thinking Like a Portfolio Manager 131 Chapter 7 The Top-Down Method 133 Investing Is a Science 133 Einstein’s Brain and the Stock Market 134 The Top-Down Method 136 Top-Down Deconstructed 141 Managing Against a Technology Benchmark 149 Chapter 8 Security Analysis 155 Make Your Selection 156 A Five-Step Process 157 Important Questions to Ask 165 Chapter 9 Upgrading Your Portfolio—Investing Strategies 175 Strategy 1: Adding Value at the Sector Level 176 Strategy 2: Adding Value at the Industry Level 178 Strategy 3: Adding Value at the Security Level 183 Strategy 4: Adding Value in a Technology Sector Downturn 184 Strategy 5: Venture Capital 185 Good Luck! 186 Glossary 187 Notes 194 About the Authors 201 Index 202
£36.00
John Wiley & Sons Inc Pharmaceutical Lifecycle Management
Book SynopsisA comprehensive guide to optimizing the lifecycle management of pharmaceutical brands The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can?and must?do to get the most out of their brands. Offering a truly immersive introduction to LCM options for pharmaceuticals, the book incorporates numerous real-life case studies that demonstrate successful and failed lifecycle management initiatives, explaining the key takeaway of each example. Filled with practical information on the process of actually writing and presenting an LCM plan,Trade Review“In conclusion, it should be stated that the authors reached their goals in providing a reference manual for potential measures that should be applied in case the life and profit of a brand are to be maximized.” (Green Processing and Synthesis, 1 March 2014) Table of ContentsAcknowledgments xvii Introduction xix Part A Lifecycle Management Business Environment 1 1. Challenges Facing the Branded Drug Industry 3 1.1 Depleted NME Pipelines/Lower R&D Efficiency 4 1.2 Higher Development Costs 8 1.3 Safety Concerns 9 1.4 Tougher Environment for Pricing, Reimbursement, and Listing 12 1.5 Increased Competition 16 1.6 Earlier Genericization 17 1.7 Faster Sales Erosion Following Patent Expiry 18 1.8 Poor Image of Branded Drug Industry 20 1.8.1 Prosperity of the Branded Drug Industry 21 1.8.2 Lack of Innovation 22 1.8.3 Marketing Spend and Tactics 22 1.8.4 Safety Issues 23 1.8.5 Keeping Generics Off the Market 24 1.9 Diversification 26 2. The Life Cycle of Industries, Technologies, and Brands 30 2.1 Diffusion of Innovations 30 2.2 The Lifecycle Curve 32 2.3 Lifecycle Phases 34 2.3.1 Development Phase 34 2.3.2 Introduction Phase 35 2.3.3 Growth Phase 35 2.3.4 Maturity Phase 36 2.3.5 Decline Phase 36 3. The Life Cycle of a Pharmaceutical Brand 38 3.1 Lifecycle Curve of Pharmaceuticals 41 3.1.1 Slow Rate of Growth during the Growth Phase 42 3.1.2 Lack of a True Maturity Phase 43 3.1.3 Precipitous Decline Phase 43 3.2 Factors Affecting Rate of Conversion to Generics 44 3.2.1 Government Policy 44 3.2.2 Disease 44 3.2.3 Size of Brand 45 3.2.4 Hospital versus Nonhospital Drug Usage 45 3.2.5 Active Substance and Other Barriers to Entry 46 3.3 The Life Cycle of a Pharmaceutical Brand 46 Part B Lifecycle Management Regulatory and Legal Environment 55 4. The Generic Approval Process 57 4.1 United States 57 4.2 Europe 59 4.3 Japan 61 5. Hatch–Waxman Legislation and Its Effects on LCM 62 5.1 Hatch–Waxman Act of 1984 62 5.2 Medicare Modernization Act of 2003 64 5.3 FDA Amendments Act of 2007 65 5.4 Q1 Program Supplemental Funding Act of 2008 66 5.5 Discussion of Hatch-Waxman Legislation 66 6. U.S. Health-Care Reform 2010 69 7. European Sector Inquiry 72 Part C Patents and Exclusivities 77 8. Patents and Other Intellectual Property Rights 79 8.1 Nonpatent Intellectual Property Rights 79 8.2 What Are Patents? 81 8.3 What Is Patentable? 83 8.3.1 Patentable Subject Matter 83 8.3.2 Novelty 84 8.3.3 Inventive Step 85 8.3.4 Utility 86 8.3.5 Disclosure 86 8.4 How Long Does a Patent Last? 87 8.5 Patent Term Restoration in the United States 87 8.6 Supplementary Protection Certificates in Europe 88 8.7 Patent Term Extension in Japan 89 8.8 How Are Patents Obtained? 89 8.9 Patent Enforcement 91 8.10 Types of Patents 92 8.10.1 Composition of Matter Patent 93 8.10.2 Medical Use Patent 93 8.10.3 Formulation Patent 94 8.11 KSR versus Teleflex—Raising the Nonobviousness Bar 94 8.12 Patent Strategy 96 9. Nonpatent Exclusivities 99 9.1 NCE Exclusivity (United States) 99 9.2 New Clinical Study Exclusivity (United States) 100 9.3 Data and Marketing Exclusivity (Europe) 100 9.4 Data Exclusivity (Japan) 101 9.5 Orphan Drug Exclusivity 101 9.6 Pediatric Exclusivity 103 9.7 180-Day Generic Product Exclusivity 105 10. Patent Settlements 107 Part D Developmental LCM 113 11. Strategic Principles of Developmental LCM 115 11.1 Developmental LCM Goal 1: Provide a Meaningful Improvement in Clinical Profile 116 11.2 Developmental LCM Goal 2: Increase the Potential Real-World Patient Potential for the Brand 118 11.3 Developmental LCM Goal 3: The Ability to Generate an ROI 120 11.4 Developmental LCM Goal 4: The Ability to Enhance Market Exclusivity of the Brand Franchise 121 12. Indication Expansion and Sequencing 123 12.1 Categories of Indication Expansion 123 13. Patient Subpopulations and Personalized Medicine 131 13.1 What Does a Good Patient Selection Strategy Look Like? 135 13.2 Patient Selection without Predictive Criteria: Post Hoc Approaches 138 13.3 What about the Patients Who Are Not Selected? 139 14. New Dosage Strengths, New Dosage Regimens 140 14.1 New Dosage Strengths 140 14.2 New Dosage Regimens 141 15. Reformulation, New Routes of Administration, and Drug Delivery 143 15.1 Reformulation and New Routes of Administration 143 15.1.1 Switch and Grow Strategy 143 15.1.2 Expand and Grow Strategy 145 15.1.3 Generic Defense 145 15.2 Drug Delivery Devices 149 16. Fixed-Dose Combinations (FDCs) and Co-Packaging 152 17. Second-Generation Products and Modified Chemistry 159 17.1 Isomerism 160 17.2 Polymorphism 161 17.3 Salts, Ethers, and Esters 162 17.4 Prodrugs and Metabolites 163 18. Other Developmental LCM Strategies 165 18.1 Manufacturing Strategies 165 18.2 White Papers and Citizen Petitions 166 Part E Commercial LCM 167 19. Strategic Principles of Commercial LCM 169 19.1 Commercial LCM Goal 1: The Ability to Drive Widespread and Preferential Patient Access to the Brand 170 19.2 Commercial LCM Goal 2: The Ability to Defend Market Access and Formulary Position 170 19.3 Commercial LCM Goal 3: The Ability to Optimize Profi tability of the Brand Franchise 171 20. Geographical Expansion and Optimization 172 20.1 Geographic Expansion 174 20.2 Harmonization and Rationalization 175 21. OTC Switching 178 21.1 What to Switch: Choosing the Best Approach 179 21.2 Where to Switch: Dealing with Intermarket Variability 181 21.3 When to Switch: Balancing the Product Life Cycle? 183 21.4 How to Make the Switch Successful: What Corporate Support Is Required? 184 22. Brand Loyalty and Service Programs 186 23. Strategic Pricing Strategies 190 23.1 Pricing Strategy and Tactics in the Launch and Growth Phases 190 23.2 Pricing Strategy and Tactics Following Patent Expiry 193 24. Generic Strategies and Tactics 198 Building a Generic Portfolio: Old versus New Thinking 202 25. Exit Strategies 204 Executing the Exit Strategy 206 Part F Biologics and Biosimilars 207 26. Biologics and LCM 209 26.1 Emergence of Biotech 209 26.2 Some Definitions 210 26.2.1 Biologics 210 26.3 Uptake and Value of Biologics 211 26.4 LCM of Biologics 213 26.4.1 Next-Generation Biologics 213 26.4.2 Reformulation 214 26.4.3 Indication Expansion 215 26.4.4 Self-Injection Devices 215 27. Biosimilars and Their Impact on Biologic LCM 217 27.1 Changing Terminology: Biogenerics, Biosimilars, and FOBs 217 27.2 Why Are Biosimilars a Big Deal? 219 27.3 How Are Biosimilars Different? 220 27.4 Biosimilar Approval Pathways 220 27.4.1 Biosimilars in Europe 220 27.4.2 Biosimilars in the United States 221 27.4.3 Biosimilars around the World 222 27.5 Substitution of Biosimilars 223 27.5.1 Automatic Substitution 223 27.5.2 Therapeutic Substitution 224 27.6 Innovator Responses to Biosimilar Threats 225 27.7 The Future for Biologics LCM 226 27.7.1 Legal Strategies in the United States 227 27.7.2 Indication Expansion in Europe 228 27.7.3 Brand Loyalty Programs and Services 229 27.8 The Emergence of the “Innovasimilar” Biopharma Company 229 27.9 Final Words 231 Part G The Integrated Brand LCM Strategy And its Implementation 233 28. Strategic Goals of LCM Brand Plans 235 28.1 Position to Market 235 28.2 Comparative Clinical Profile versus Gold Standard 237 28.3 Level of Market Unmet Need 237 29. Ten Keys to Successful LCM 238 29.1 Excellent Functional Expertise 238 29.1.1 Patent Attorneys 239 29.1.2 Regulatory Affairs 240 29.1.3 Clinical Development 240 29.1.4 Formulation Scientists 241 29.1.5 Marketing and Sales 242 29.1.6 Manufacturing 243 29.2 Visible Management Support 244 29.3 Unambiguous Ownership 245 29.4 An Early Start 246 29.5 A Robust “Broad to Bespoke” Process 248 29.6 Focus on “High LCM Value Brands” 249 29.7 Adequate Resources 250 29.8 Measurements and Rewards 250 29.9 Training and Support 252 29.10 Realism 252 30. Organizational Structures and Systems for Ensuring Successful LCM 254 30.1 Organization of Project and Brand Management 254 30.1.1 Functional Structure 255 30.1.2 Project Structure 255 30.1.3 Matrix Structure 257 30.2 Project and Brand LCM Structures 259 30.3 LCM Center of Excellence 263 30.4 Composition of the LCM CoE 266 31. The LCM Process: Description, Timing, and Participants 268 31.1 Purpose of the LCM Process 268 31.2 Timing of the LCM Process 269 31.3 Description of the LCM Process 271 Part H Integrating LCM with Portfolio Management 277 32. Principles of Portfolio Management 279 33. LCM Projects in the Development Portfolio 284 34. Managing Established Brand Portfolios 286 34.1 What Do You Do with a Priority Established Brand? 288 34.2 What about the Nonpriority Brands? 289 34.3 Building the Ideal Established Brands Portfolio 290 Conclusions 291 Appendix: Case histories 294 A.1 Market and Product-Shaping Dynamics in Action 294 Alzheimer’s Disease Therapies: Aricept®, Exelon®, and Reminyl®/Razadyne® 294 Learnings 297 A.2 Optimizing Clinical Profi le versus Gold Standards 298 Angiotensin II Receptor Blockers (ARBs): Cozaar®, Micardis®, and Benicar® 298 Learnings 299 A.3 Partnering to Ensure Reimbursement and Collection of Cost-Effectiveness Data 299 Aricept 299 Learnings 301 A.4 Active Metabolites and Late-Listed Patents 301 Buspar® 301 Learnings 303 A.5 A Fixed-Dose Combination (FDC) That Could Not Fail, or Could It? 303 Caduet® 303 Learnings 304 A.6 Indication Expansion 305 Certican®/Zortress® and Afi nitor® 305 Learnings 306 A.7 Killing a Franchise through Over-the-Counter (OTC) Switching 307 Claritin® 307 Learnings 308 A.8 Moving FDCs to the Fore in Diabetes 308 Diabetes Therapies: Glucophage®, Avandia®, Actos®, and Januvia® 308 Learnings 310 A.9 FDCs and Multiple Dosage Strengths 310 Diovan® and Tekturna®/Rasilez® 310 Learnings 312 A.10 Building a Compliance Support Program 312 Enbrel® 312 Learnings 314 A.11 Targeting Responders with High-Price Cancer Agents 314 Erbitux® 314 Learnings 315 A.12 Failure of a “No-Brainer” LCM Strategy 315 Exubera® 315 Learnings 319 A.13 At-Risk Launches and Prodrug Patents 320 Famvir® 320 Learnings 321 A.14 New Dosages, FDC, and Patent Litigation 322 Fosamax® 322 Learnings 324 A.15 High Regulatory Hurdles for Lifestyle Drugs 325 Girosa® 325 Learnings 327 A.16 Big Money from Orphan Indications 327 Gleevec® 327 Learnings 329 A.17 Not Giving Up on a Controversial Brand 330 Iressa® 330 Learnings 332 A.18 Expanding a Medical Aesthetics Franchise with an Ophthalmic Drug 332 Latisse® 332 Learnings 334 A.19 Patent Expiry of the Biggest Drug Brand Ever 335 Lipitor® 335 Learnings 336 A.20 Early Out-Licensing by Biotech: Take the Money and Run 336 Macugen® 336 Learnings 338 A.21 Codevelopment and Comarketing Deals End in a Megamerger 338 Merck and Schering-Plough: Zetia®/Vytorin® and Claritin/Singulair® 338 Zetia/Vytorin 339 Claritin/Singulair 342 Learnings 343 A.22 A Hugely Successful LLCM Switch Strategy: Business Needs and Reputational Issues Collide 344 Prilosec® and Nexium 344 The Facts 344 The Public Reaction 345 Learnings 347 A.23 Combining Production Outsourcing with Settlement with a Generic Competitor 349 Nexium 349 Learnings 351 A.24 Reformulating for Success in Osteoporosis 351 Osteoporosis Drugs: Fosamax, Actonel®, Boniva®, and Aclasta® 351 Learnings 353 A.25 Isomerism, Polymorphism, and Settlements 354 Plavix® 354 Learnings 355 A.26 Payers versus Brand for Patient Selection 356 Plavix and Brilinta 356 Learnings 357 A.27 Litigation Can Delay Generic Entry in the OTC Field Too 358 Prilosec OTC 358 Learnings 359 A.28 Inconsistent Court Decisions Can Hurt Both Brandand Generic Companies 360 Protonix® 360 Learnings 361 A.29 Holding on to an Antipsychotic Franchise 362 Risperdal®/Invega® 362 Learnings 363 A.30 LCM Creates an Almost Immortal Brand 364 Voltaren® 364 Learnings 365 A.31 LCM of a Women’s Health Franchise 366 The Yasmin® Family 366 Learnings 368 A.32 Indication Expansion/New Dosage Strength 369 Zometa/Reclast® (Aclasta) 369 Learnings 370 Index 371
£74.66
John Wiley & Sons Inc Regulatory Compliance
Book SynopsisThis book guides the reader through FDA regulation guidelines and outlines a comprehensive strategy for cost reduction in regulatory affairs and compliance. This book explains six strategies to cost-effectively comply with FDA regulations while maintaining product safety and improving public access through cost controls. It provides useful and practical guidance through industry case studies from pharmaceutical, biotech, and medical device industries.Table of ContentsPREFACE. Chapter 1. Controlling Regulatory Costs. Chapter 2. Clear Operation Definitions of Requirements. Chapter 3. Pre-Regulatory Audits. Chapter 4. Quality by Design. Chapter 5. Outsourcing. Chapter 6. Electronic Submissions. Chapter 7. EMEA/FDA Inspections. Chapter 8. Managing FDA Inspections. Chapter 9. Risk Assessment. Chapter 10. Cases. Chapter 11. Cost Containment Analysis. Chapter 12. Managing Regulation In Times of Chaos. Chapter 13. International Regulation. Chapter 14. Cost Contained Regulatory Compliance. Chapter 15. Future. BIBLIOGRAPHY. INDEX .
£90.86
Wiley Pharma Supply Chain Delivering Patient Value for Pharmaceuticals and Biologics
Book SynopsisThis book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector.Trade Review"A recommended read for all wishing to shift performance to greater levels." (Supply Management, 1 February 2012) "This book is ideal reading for those entering or currently working in the field of supply chain management, such as clinical supply managers, or those in operations or production and planning ... This book would be an excellent resource for small pharmaceutical companies that may have limited experience of supply chain implementation or outsourcing, giving a thorough overview of the process and plenty of food for thought." (The Pharmaceutical Journal, 16 November 2011) "This is a solid text that is equally suitable for the newcomer or experienced profesional in the pharmaceutical/biologics industries . . . Overall, I recommend the book for its educational perspective on the industry and the significance of effective SCM for its future success." (Quality World, 1 July 2011)Table of ContentsCONTRIBUTORS xiii PREFACE xxi I SURVEYING AND MAPPING THE TERRITORY 1 1 Setting a Transformational Agenda 3 1.1 Aims and Aspirations of the Book 3 1.2 Book Format 5 1.3 Intended Readership 6 1.4 A Book About Two Worlds in Contrast 8 1.5 The Pharmaceutical Lottery 8 1.6 Supply Chain Management in Context 17 1.7 The History of Supply and Value Generation 22 1.8 The Development of Processes to Manage the Supply Chain 24 1.9 Life in SCM 25 1.10 Moving Forward 26 2 Plotting a Course to Patient Value 29 2.1 Why Focus on Patient Value? 29 2.2 Where Does the Patient Currently Fit? 29 2.3 Why Is It Necessary to Plot a Course? 33 2.4 Understanding How the Course Is Presently Set 39 2.5 Capturing Value for Patients 42 3 Pharmaceutical Drug Development 45 3.1 Drug Development’s Role in the Supply Chain 45 3.2 Introduction to Drug Development 47 3.3 The Medicinal Product 48 3.4 Clinical Trials 49 3.5 Related Development Programs 52 3.6 Managing Clinical Programs 57 3.7 Regulatory Affairs and Authorities 58 3.8 Supply Chain Management in Development Programs 65 3.9 Manufacture and Supply of Commercial Products 68 3.10 Supply Chain Management for Commercial Products 69 4 End-to-End Pharmaceutical Supply Chains 73 4.1 Introduction 73 4.2 Where Does Responsibility for the Supply Chain Lay? 74 4.3 Sponsoring Companies, License Holders, and Their Supply Chains 75 4.4 Supply Chains for Small-Molecule Products 76 4.5 Starting at the Final Destination 78 4.6 How Drugs Enter the Body 78 4.7 Design of Drug Delivery Systems 79 4.8 What This Means for the Supply Chain 82 4.9 Key Aspects of GMP and GDP in Relation to SCM 82 4.10 Overview of the Stages on Route to Patient Delivery 86 4.11 Manufacture and Supply of Biological Entities 90 5 Why Pharma Supply Chains Don’t Perform 103 5.1 Supply Chain Underperformance 103 5.2 Is There a Case to Answer? 103 5.3 Birth to Infancy: The Supply Chain Critical Stage 104 5.4 Commercial Supply Under the Patent Protection Umbrella 111 5.5 What This Means for the Pharmaceutical Supply Chain 116 II BUILDING A KNOWLEDGE FOUNDATION IN SCM 125 6 Supply Chain Management as a Competitive Weapon 127 6.1 Competition and Business Strategy 127 6.2 The Marketing Mix 128 6.3 Porter’s Five Forces 128 6.4 Porter’s Generic Competitive Strategies 129 6.5 Porter’s Value Chain 129 6.6 Competitive Strategy and Customers 133 6.7 The Japanese Experience 142 6.8 Total Quality Management 142 6.9 Lean Thinking 143 6.10 Focusing on Value for Money 146 6.11 SCM Processes in Competitive Strategy 148 6.12 SCM in Biotech and Virtual Companies 150 6.13 Competition in Pharmaceuticals 152 7 Supply Chain Management Holistic 155 7.1 The Relevance of SCM to Pharmaceuticals 155 7.2 Production Systems and the SCM Holistic 155 7.3 The Core of SCM 156 7.4 First Principle of SCM 156 7.5 Supply Chains as a Series of Interconnected Systems 158 7.6 Processes to Manage the Supply Chain 160 7.7 A Word About Processes 161 7.8 How the SCM Processes Should Mesh Together 163 7.9 Production and Inventory Control 163 7.10 Strategic Procurement 163 7.11 Transportation, Storage, and Distribution 164 7.12 Information Systems and Technology 164 7.13 Improvement 165 8 Production and Inventory Control 167 8.1 Core Mission 167 8.2 First Principles of Production and Inventory Control 167 8.3 The Wholesome Trinity in P&IC 174 8.4 The Wholesome Trinity and Customer Expectations 177 8.5 Leveraging the Wholesome Trinity 179 8.6 The Impact of Variety on Supply Chains 180 8.7 Designing Appropriate Production Systems 183 9 Strategic Procurement 187 9.1 Core Mission 187 9.2 The Purchasing Portfolio 188 9.3 The Process of Procurement 195 9.4 Strategic Sourcing and Planning 198 9.5 Outsourcing 201 9.6 Basic Principles in Contracting for Supply 206 9.7 Finally, Typical Organizational Tension over Procurement 213 10 Transportation, Storage, and Distribution 215 10.1 Defining the Core Mission 215 10.2 International Trade and Commerce 217 10.3 The World Trade Organization 217 10.4 Intermediary Arrangements 220 10.5 Terms of Trade: Incoterms 223 10.6 Ownership of Goods: Title 225 10.7 Third-Party Logistics Providers 226 10.8 Customs 227 10.9 Shipping Regulations Relating to Materials 229 10.10 A Finishing Note 230 11 Information Systems and Information Technology 233 11.1 Overview 233 11.2 Brief Lay History of Computer Systems Development 234 11.3 Important Perspectives on Information Systems 236 12 Improvement 255 12.1 Why Improve? 255 12.2 Improvement and Production Systems 257 12.3 The Improvement Journey 258 13 Bringing the Holistic Together 277 13.1 Setting the Scene 277 13.2 The Process Explained 278 13.3 Developing an Action Agenda 285 13.4 Case Study 289 III PLANNING AND EXECUTING SUPPLY CHAIN CHANGE 293 14 Improvement in Pharmaceuticals 295 14.1 Where Are We Now? 295 14.2 Subsequent Developments Since Inception 310 14.3 A Blueprint for Quality by Design 311 15 Exemplar Thinking in Organizational Improvement 335 15.1 Where Are We Now? 335 15.2 What Is Meant by "Exemplar"? 338 15.3 A Dialogue on Exemplar Improvement 338 15.4 An Approach to SCM Based on Systems Thinking 357 16 Building a Foundation for Sustainable Change 363 16.1 Focus on the Individual 363 16.2 Individuals as Leaders 368 16.3 Individuals as Motivators and the Motivated 370 16.4 Individuals as Group Members 372 16.5 Individuals as Participants in Cultural Change 376 16.6 Case Study: Miles Ltd., Bridgend, Glamorgan 378 17 A Cure for the Pharmaceutical Supply Chain 395 17.1 What Is the Disease State? 395 17.2 What Is the Label Claim for the Medicine? 396 17.3 What Will Life Hold Without the Medicine? 397 17.4 What Is This Better Way to Develop Drugs? 397 17.5 Full-Scale Production of Drugs 407 17.6 What Are the Barriers to Change? 410 17.7 What Are the Potential Benefits of Change? 413 17.8 Defining the Art of the Possible 414 17.9 Ending with the Beginning 417 END NOTES 419 INDEX 429
£87.26
John Wiley & Sons Inc Manufacturing Processes and Systems
Book SynopsisThis book covers everything an engineer needs to know about manufacturing systems and processes.Table of ContentsThe Manufacturing System.Nature and Properties of Materials.Production of Ferrous Metals.Production of Nonferrous Metals.Foundry Processes.Contemporary Casting Processes.Basic Machine Tool Elements.Sawing, Broaching, Shaping, and Planing.Grinding and Abrasive Processes.Pressworking and Operations.Heat Treating.Plastic Materials and Processes.Electronic Fabrication.Nontraditional Processes and Powder Metallurgy.Thread and Gear Working.Operations Planning.Geometric Dimensioning and Tolerancing.Metrology and Testing.Quality Systems.Computer Numerical Control Systems.Process Automation.Operator-Machine Systems.Cost Estimating.Bibliography.Photo Credits.Index.
£200.66
John Wiley & Sons Inc Project Management in Manufact Wiley Series in
Book SynopsisThis book examines the use of project management techniques in all phases of manufacturing. It explores the applicability of project management techniques to general business methods (planning, scheduling, and controlling). It discusses the role of project management in quality control.Table of ContentsManufacturing Systems Analysis. Elements of Project Management. PERT/CPM Techniques. Resource Management. Learning Curve Analysis. Forecasting and Inventory Control. Manufacturing Economic Analysis. Data Analysis and Management. Expert System for Production Scheduling. Computer Simulation and Software Tools. Space Shuttle Challenger Accident: Case Study of High Tech ProjectFailure. Bibliography. Appendix. Index.
£138.56
John Wiley & Sons The Executives Guide To Mrp Ii
Book SynopsisOliver Wight is one of the pioneers of Manufacture Resource Planning (MRPII). Here he introduces the essential concepts and benefits of MRPII in a practical format with easy-to-follow question-and-answer format.Table of ContentsWhy the Excitement About MRP II Today? Does MRP II Apply to My Business? What Results Can We Expect? What Does MRP II Cost? Why Should the Executive Care? What Must Be Done to Be Successful with MRP II? How Do We Implement MRP II? How Do We Manage with MRP II? References. The Implementation Plan. Excerpts from the Oliver Wight ABCD Checklist.
£36.00
John Wiley & Sons Inc Advanced Composites Manufacturing
Book SynopsisA state-of-the-art look at advanced composites processing and manufacturing-from leading academic and industry experts Advanced Composites Manufacturing combines cutting-edge coverage of the scientific fundamentals of composites processing with an in-depth treatment of the major manufacturing processes for advanced composite materials.Table of ContentsA Brief Introduction to Composite Materials and Manufacturing Processes (T. Gutowski). The Processing Science of Reactive Polymer Composites (J. Kardos). The Processing Science of Thermoplastic Composites (J. Muzzy & J. Colton). The Elastic Deformation of Fiber Bundles (T. Gutowski & G. Dillon). Processing of Textile Preforms (F. Ko & G. Du). The Autoclave Processing of Composites (G. Dillon, et al.). Pultrusion of Composites (J. Fanucci, et al.). Forming of Advanced Composites (C. Tucker). Filament Winding Process Model for Thermosetting Matrix Composites (G. Springer). Liquid Composite Molding (L. Lee). Process Control of Thermosetting Composites: Context and Review (D. Hardt). Joining of Composites (A. Benatar, et al.). Cost, Automation, and Design (T. Gutowski). Index.
£224.96
Wiley-Blackwell Food Processing
Book SynopsisThis book covers the growth, economic development, and business management of the US commercial food processing industry. Topics include the strategic options of food processors when facing the many distribution channels and sourcing options currently available; new processing and information technologies; the effect of biotechnological developments on the food processing industry, and an analysis of whether the food processing sector has participated in the overall improvement of the US economy.Table of ContentsBrief History of the Industries. Processing in the U.S. Food System. Industrial Structure and Business Organization. Industry Growth. Geographic Location. Input Utilization. Input Procurement Strategies. Household Demand for Food. Distribution Channels for Food. Product and Promotion Strategies. Technological Change. The Globalization of Food Processing. The Futures of Food Processing. Appendices. Bibliography. Index.
£175.46
John Wiley & Sons Inc Food Canning Technology
Book SynopsisFood Canning Technology Edited By Jean Larousse Bruce E. Brown This book offers a comprehensive review of the various scientific, technological, and economic aspects of food product preservations.Table of ContentsFrom the Contents: Meat and Fish/ Fruit and Vegetables/ The Microbiological Aspects/ Thermobacteriology/ Reception and Preparation of Fruit and Vegetables for Canning/ Fruit and Vegetables Preparation - Practical Applications/ Preparation of Meat and Meat Products/ Preparation of Fish and Shellfish for Canning/ Containers for Canned Foods/ Controlling Container Quality/ Heat Penetration in Canned Foods - Theoretical Considerations/ Determination of Heat Penetration Parameters/ Thermal Process - Development, Validation, Adjustment and Control/ Thermal Processing Equipment Systems/ Aseptic Processing and Packaging - Methods, Equipment and Materials/ Aseptic Processing and Packaging - Commercial Applications/ Post-Process Container Handling and Storage/ Quality Assurance of End Products
£254.66
Wiley Handbook of Citrus ByProducts and Processing Technology
Book SynopsisThis book provides a complete treatment of citrus by-products - including data, research and technological developments. * Emphasizes the manufacturing and utilization of citrus by-products from raw material residues of juice extraction and recovery Process descriptions include those for essential oils, d-limonene, dried pulp cattle feeds and molasses, peel products, pectin, flavonoids, pulp wash and pulp products, bioconversion, and other productsTrade Review"The author and publishers are to be congratulated on the high standard of publication." (Food & Biproducts Processing, June 2000) "...this book will make an excellent starting point for anyone wishing to know about the handling of oranges and related fruits..." (Food Chemistry, Vol 71, 2000)Table of ContentsThe Citrus Industry. Fruit Growing, Harvesting, Handling, and Grading for Processing. Composition, Properties, and Evaluation of Fruit Components. Juice Processing Operations. Single-Strength Juices and Concentrate. Juice Chemical Reactions, Product Stability, and Packaging. Pulp Washing, Juice Pulp Recovery, and Utilization. Whole Juice Cells, Drum-Dried Juice Sacs, and Sections. Peel Fiber, Cloud, and Products. Dried Pulp, Pellets, and Molasses. Essential Oils and Essences. d-Limonene. Pectin. Bioconversion Products. Flavonoids and Limonoids. Seed Products. Nutraceuticals, Mystical Substances, and By-Products.
£175.46
John Wiley & Sons Inc Statistical Methods for Six SIGMA
Book SynopsisA guide to achieving business successes through statistical methods Statistical methods are a key ingredient in providing data-based guidance to research and development as well as to manufacturing. Understanding the concepts and specific steps involved in each statistical method is critical for achieving consistent and on-target performance.Trade Review"I highly recommend this book to anyone interested in applying statistics to solve problems." (Journal of Food Quality, October 2004) "…an interesting collection of material in nice summary form…" (Journal of the American Statistical Association, December 2004) "Overall, Statistical Methods for Six Sigma in R & D and Manufacturingoffers some good insights and practical views of the statistical concepts covered." (Technometrics, August 2004, Vol. 46, No. 3) "...covers a large number of useful statistical methods compactly...contains a wealth of case studies and examples..." (Food Trade Review, May 2004) “...can be used as a reference or as a self-study...also as a textbook for an engineering statistics course...recommended...” (E-Streams, Vol. 7, No. 3)Table of Contents1. Introduction. 2. Basic Statistics. 2.1 Descriptive Statistics. 2.2 Statistical Distributions. 2.3 Confidence Intervals. 2.4 Sample Size. 2.5 Tolerance Intervals. 2.6 Normality, Independence and Homoscedasticity. 3. Comparative Experiments and Regression Analysis. 3.1 Hypothesis Testing Framework. 3.2 Comparing Single Population. 3.3 Comparing Two Populations. 3.4 Comparing Multiple Populations. 3.5 Correlation. 3.6 Regression Analysis. 4. Control Charts. 4.1 Role of Control Charts. 4.2 Logic of Control Limits. 4.3 Variable Control Charts. 4.4 Attribute Control Charts. 4.5 Interpreting Control Charts. 4.6 Key Success Factors. 5. Process Capability. 5.1 Capability and Performance Indices. 5.2 E stimating Capability and Performance Indices. 5.3 Six-Sigma Goal. 5.4 Planning for Improvement. 6. Other Useful Charts. 6.1 Risk-based Control Ch arts. 6.2 Modified Control Limit Chart. 6.3 Moving Average Control Chart. 6.4 Short Run Control Charts 6.5 Charts for Non-Normal Distributions. 7. Variance Components Analysis. 7.1 Chart (Random Factor). 7.2 One-way Classification (Fixed Factor). 7.3 Structured Studies and Variance Components. 8. Quality Planning with Variance Components. 8.1 Typical Manufacturing Application. 8.2 Economic Loss Functions. 8.3 Planning for Quality Improvement. 8.4 Application to Multi-Lane Manufacturing Process. 8.5 Variance Transmission Analysis. 8.6 Application to a Factorial Design. 8.7 Variance Components and Specifications. 9. Measurement Systems Analysis. 9.1 Statistical Properties of Measurement Systems. 9.2 Acceptance Criteria. 9.3 Calibration Study. 9.4 Stability and Bias Study. 9.5 Repeatability and Reproducibility (R&R) Study. 9.6 Robustness and Intermediate Precision Studies. 9.7 Linearity Study. 9.8 Method Transfer Study. 9.9 Calculating Significant Figures. 10. What Color is Your Belt? 10.1 Test. 10.2 Answers. Appendix A: Tail Area of Unit Normal Distribution. Appendix B: Probability Points of the t Distribution with v Degrees of Freedom. Appendix C: Probability Points of the x2 Distribution with v Degrees of Freedom. Appendix D1.k Values for Two-Sided Normal Tolerance Limits. Appendix D2.k Values for One-Sided Normal Tolerance Limits. Appendix E1: Percentage Points of the F Distribution: Upper 5% Points. Appendix E2: Percentage Points of the F Distribution: Upper 2.5% Points. Appendix F: Critical Values of Hartley's Maximum F Ratio Test for Homogeneity of Variances. Appendix G: Table of Control Chart Constants. Glossary Of Symbols. References. Index.
£123.26
John Wiley & Sons Inc Management for Quality 25 Wiley Series in Systems
Book SynopsisWith the moves toward globalisation, outsourcing, and the rise of the knowledge-worker workforce, the internal and external environments of high technology enterprise have changed radically. As a consequence, the role and function of the contemporary manager have changed as well.Trade Review"…the authors managed to describe all major aspects on which quality can be built. I use this book as a 'bible' for organizational renewal." (IIE Transactions on Operations Engineering)Table of ContentsIntroduction. PART I: A SYSTEMIC APPROACH TO ORGANIZATIONAL TRANSFORMATION. Chapter 1. A Systems View Of Organization. Chapter 2. Systems: A General Concept. Chapter 3. The Total Continuous Process of Improvement and Innovation (TCPI?) Marco System. PART II: MANAGING A KNOWLEDGE-BASED ORGANIZATON. Chapter 4. Organizational Learning. Chapter 5. Systemic Problem Solving (SPS) as an Effective Way of Learning. Chapter 6. Knowledge-Based Innovation. Chapter 7. Knowledge Managers and Knowledge Workers. Chapter 8. Knowledge Transfer and Knowledge Management. PART III: MANAGING IN A GLOBAL ENVIRONMENT. Chapter 9. On the Road to Globalization. Chapter 10. Managing Mergers, Acquisitions, and Other Strategic Alliances. Chapter 11. Globalization and Culture. PART IV: SOME ASPECTS OF MANAGING QUALITY. Chapter 12. Some Fundamental Concepts of Managing Quality. Chapter 13. Managing Variation: A Requisite for Quality. Chapter 14. Some Major Quality Initiatives. Chapter 15. Achieving High Quality Through Transformational Changes. PART V: RESHAPING THE ORGANIZATIONAL CULTURE. Chapter 16. The System of the Organizational Culture. Chapter 17. Managing the Core of the Organizational System. Chapter 18. Values, Behavioral Standards, and Business Ethics. Chapter 19. Symbols, Symbolic Actions, and Metaphors. Chapter 20. Understanding an Organization's Behavior.
£125.96